INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17101, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Water-Electrolyte Imbalance', 'Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure.  Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17102, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Diarrhea', 'Potassium chloride liquid suspension contains the stool softener, docusate sodium, as a dispersing agent.  Clinical studies with potassium chloride liquid suspension indicate that minor changes in stool consistency may be common though usually well tolerated.  However, patients may rarely experience diarrhea or cramping abdominal pain.  Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed potassium chloride liquid suspension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17103, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Diarrhea', 'Potassium chloride liquid suspension contains the stool softener, docusate sodium, as a dispersing agent.  Clinical studies with potassium chloride liquid suspension indicate that minor changes in stool consistency may be common though usually well tolerated.  However, patients may rarely experience diarrhea or cramping abdominal pain.  Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed potassium chloride liquid suspension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17104, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Diarrhea', 'Potassium chloride liquid suspension contains the stool softener, docusate sodium, as a dispersing agent.  Clinical studies with potassium chloride liquid suspension indicate that minor changes in stool consistency may be common though usually well tolerated.  However, patients may rarely experience diarrhea or cramping abdominal pain.  Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed potassium chloride liquid suspension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17105, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Diarrhea', 'Potassium chloride liquid suspension contains the stool softener, docusate sodium, as a dispersing agent.  Clinical studies with potassium chloride liquid suspension indicate that minor changes in stool consistency may be common though usually well tolerated.  However, patients may rarely experience diarrhea or cramping abdominal pain.  Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed potassium chloride liquid suspension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17106, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Diarrhea', 'Potassium chloride liquid suspension contains the stool softener, docusate sodium, as a dispersing agent.  Clinical studies with potassium chloride liquid suspension indicate that minor changes in stool consistency may be common though usually well tolerated.  However, patients may rarely experience diarrhea or cramping abdominal pain.  Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed potassium chloride liquid suspension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17107, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17108, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17109, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17110, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17111, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Dehydration', 'Administration of potassium salts in severe dehydration may predispose to renal impairment.  Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17112, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17113, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17114, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17115, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17116, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Paralyses, Familial Periodic', 'Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita.  Therapy with potassium preparations should be administered cautiously in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17117, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17118, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17119, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17120, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17121, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Hyperkalemia', 'The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest.  Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17122, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17123, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17124, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17125, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17126, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Kidney Diseases', 'The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia.  Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest.  Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency).  Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval).  Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).  Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17127, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17128, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17129, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17130, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17131, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Gastrointestinal Diseases', 'The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes.  Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact.  Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years.  Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium.  Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation.  Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid.  Potassium liquids should be diluted prior to consumption.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17132, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17133, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17134, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17135, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17136, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17137, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17138, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17139, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17140, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17141, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17142, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17143, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17144, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17145, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17146, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Acid-Base Imbalance', 'Alkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions.  Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis.  Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release.  Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function.  Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17147, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17148, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17149, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17150, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17151, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Acidosis', 'Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium.  Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17152, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Arrhythmias, Cardiac', 'The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias.  Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy).  Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17153, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Arrhythmias, Cardiac', 'The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias.  Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy).  Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17154, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Arrhythmias, Cardiac', 'The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias.  Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy).  Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17155, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Arrhythmias, Cardiac', 'The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias.  Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy).  Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17156, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Arrhythmias, Cardiac', 'The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias.  Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy).  Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17157, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Unconsciousness', 'Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously.  Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17158, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Unconsciousness', 'Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously.  Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17159, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Unconsciousness', 'Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously.  Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17160, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Unconsciousness', 'Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously.  Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17161, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Unconsciousness', 'Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously.  Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17162, 3788, 'Polyethylene glycol (3350 with electrolytes)', 'Seizures', 'PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness.  The seizure cases were associated with electrolyte abnormalities and low serum osmolality.  Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17163, 11122, 'Polyethylene glycol (3350 with electrolytes)', 'Seizures', 'PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness.  The seizure cases were associated with electrolyte abnormalities and low serum osmolality.  Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17164, 27832, 'Polyethylene glycol (3350 with electrolytes)', 'Seizures', 'PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness.  The seizure cases were associated with electrolyte abnormalities and low serum osmolality.  Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17165, 27833, 'Polyethylene glycol (3350 with electrolytes)', 'Seizures', 'PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness.  The seizure cases were associated with electrolyte abnormalities and low serum osmolality.  Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17166, 27835, 'Polyethylene glycol (3350 with electrolytes)', 'Seizures', 'PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness.  The seizure cases were associated with electrolyte abnormalities and low serum osmolality.  Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17167, 21113, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17168, 21114, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17169, 21115, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17170, 21871, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17171, 21872, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17172, 21873, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17173, 21917, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17174, 21918, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17175, 21961, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17176, 24964, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17177, 24966, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17178, 24968, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17179, 33109, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17180, 33110, 'Pitavastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17181, 21113, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17182, 21114, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17183, 21115, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17184, 21871, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17185, 21872, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17186, 21873, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17187, 21917, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17188, 21918, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17189, 21961, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17190, 24964, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17191, 24966, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17192, 24968, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17193, 33109, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17194, 33110, 'Pitavastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17195, 21113, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17196, 21114, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17197, 21115, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17198, 21871, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17199, 21872, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17200, 21873, 'Pitavastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
